Argos Therapeutics Incorporated (NASDAQ:ARGS) Just Reported Decreased Shorts

January 12, 2018 - By Vivian Currie

 Argos Therapeutics Incorporated (NASDAQ:ARGS) Just Reported Decreased Shorts

Investors sentiment increased to 0.63 in Q3 2017. Its up 0.09, from 0.54 in 2017Q2. It improved, as 13 investors sold Argos Therapeutics, Inc. shares while 6 reduced holdings. 8 funds opened positions while 4 raised stakes. 2.64 million shares or 38.27% more from 1.91 million shares in 2017Q2 were reported.
Two Sigma owns 149,999 shares for 0% of their portfolio. Royal Comml Bank Of Canada has invested 0% of its portfolio in Argos Therapeutics, Inc. (NASDAQ:ARGS). Blackrock holds 0% or 7,054 shares. Deutsche State Bank Ag has invested 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Guggenheim Capital Limited has 27,984 shares. Millennium Mngmt stated it has 0% in Argos Therapeutics, Inc. (NASDAQ:ARGS). Hightower Advsr Limited owns 32,071 shares for 0% of their portfolio. National Bank & Trust Of New York Mellon Corporation stated it has 74,379 shares. Moreover, California Employees Retirement Sys has 0% invested in Argos Therapeutics, Inc. (NASDAQ:ARGS) for 94,800 shares. Northern Trust invested in 43,244 shares. National Bank Of America Corporation De owns 750 shares or 0% of their US portfolio. Virtu Financial Llc owns 47,244 shares for 0% of their portfolio. Keybank Association Oh has 0% invested in Argos Therapeutics, Inc. (NASDAQ:ARGS) for 119,515 shares. Stifel Fincl owns 65,550 shares or 0% of their US portfolio. Bnp Paribas Arbitrage invested 0% of its portfolio in Argos Therapeutics, Inc. (NASDAQ:ARGS).

The stock of Argos Therapeutics Incorporated (NASDAQ:ARGS) registered a decrease of 41.44% in short interest. ARGS’s total short interest was 4.31M shares in January as published by FINRA. Its down 41.44% from 7.36M shares, reported previously. With 3.63 million shares average volume, it will take short sellers 1 days to cover their ARGS’s short positions. The short interest to Argos Therapeutics Incorporated’s float is 20.07%.

The stock decreased 0.90% or $0.0015 during the last trading session, reaching $0.1653. About 2.43 million shares traded. Argos Therapeutics, Inc. (NASDAQ:ARGS) has declined 92.57% since January 12, 2017 and is downtrending. It has underperformed by 109.27% the S&P500.

Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company has market cap of $14.53 million. The firm develops immunotherapies based on its proprietary technology platform, Arcelis. It currently has negative earnings. The Company’s product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer.

Argos Therapeutics, Inc. (NASDAQ:ARGS) Ratings Coverage

Among 4 analysts covering Argos Therapeutics (NASDAQ:ARGS), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Argos Therapeutics has $18 highest and $12 lowest target. $14.25’s average target is 8520.69% above currents $0.1653 stock price. Argos Therapeutics had 6 analyst reports since November 16, 2015 according to SRatingsIntel. The rating was maintained by FBR Capital with “Outperform” on Monday, November 16. The firm has “Hold” rating by Needham given on Thursday, September 21. The firm earned “Buy” rating on Tuesday, November 17 by Needham. The rating was maintained by Roth Capital with “Buy” on Tuesday, April 19. As per Wednesday, March 9, the company rating was maintained by JMP Securities. The rating was maintained by FBR Capital on Thursday, August 11 with “Outperform”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.